Dakota Gallivan - Reata Pharmaceuticals VP Officer
| RETADelisted Stock | USD 109.67 3.31 2.93% |
Insider
Dakota Gallivan is VP Officer of Reata Pharmaceuticals
| Phone | 972 865 2219 |
| Web | https://www.reatapharma.com |
Reata Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3766) % which means that it has lost $0.3766 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1239) %, meaning that it created substantial loss on money invested by shareholders. Reata Pharmaceuticals' management efficiency ratios could be used to measure how well Reata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Reata Pharmaceuticals currently holds 119.46 M in liabilities with Debt to Equity (D/E) ratio of 2.08, implying the company greatly relies on financing operations through barrowing. Reata Pharmaceuticals has a current ratio of 10.39, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Reata Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Rebecca MD | Madrigal Pharmaceuticals | 72 | |
| Pierre BSc | CureVac NV | 50 | |
| LLM LLM | CureVac NV | 52 | |
| William JD | Akero Therapeutics | 51 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Robert Waltermire | Madrigal Pharmaceuticals | 60 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Katherine Tuminello | Krystal Biotech | N/A | |
| Alex Kane | PTC Therapeutics | N/A | |
| MS MBA | Krystal Biotech | 59 | |
| Eric Pauwels | PTC Therapeutics | 63 | |
| Louise RodinoKlapac | Sarepta Therapeutics | 46 | |
| Howard Horn | Vir Biotechnology | 46 | |
| Klaus Frueh | Vir Biotechnology | 64 | |
| George Scangos | Vir Biotechnology | 76 | |
| Marianne Mancini | Viking Therapeutics | 59 | |
| Louis MD | Vir Biotechnology | N/A | |
| Steven Rice | Vir Biotechnology | 64 | |
| Timothy Rolph | Akero Therapeutics | 70 | |
| Paul MD | Madrigal Pharmaceuticals | 81 | |
| Mary Jenkins | Sarepta Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 |
Reata Pharmaceuticals Leadership Team
Elected by the shareholders, the Reata Pharmaceuticals' board of directors comprises two types of representatives: Reata Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reata. The board's role is to monitor Reata Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reata Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reata Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Warren Huff, Chairman of the Board and Presidentident, CEO | ||
| Christian Wigley, VP Officer | ||
| Bhaskar Anand, VP Officer | ||
| Michael Wortley, Vice President Chief Legal Officer | ||
| Dawn Bir, Chief Commercial Officer | ||
| Colin MD, Ex Officer | ||
| Manmeet Soni, CFO COO | ||
| Elaine Castellanos, Consultant | ||
| Steve Harman, VP Officer | ||
| Dakota Gallivan, VP Officer |
Reata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reata Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (14.55) % | |||
| Current Valuation | 6.4 B | |||
| Shares Outstanding | 33.59 M | |||
| Shares Owned By Insiders | 4.10 % | |||
| Shares Owned By Institutions | 88.46 % | |||
| Number Of Shares Shorted | 2.6 M | |||
| Price To Earning | (28.13) X | |||
| Price To Book | 285.94 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |